Pages

Thursday, 19 September 2013

Losers (part 3) - Intuitive Surgical

At the start of the week, I wrote a post highlighting some losers in the FT Global 500 index I would be taking a look at.  I have left myself a small company called Apple for tomorrow (one year anniversary of the peak share price today, so a good time to be looking at it) and will focus on Intuitive Surgical today.

Intuitive Surgical was down in the market excitement following the announcement of the non-taper.  It capped a pretty poor last few months for the company and left the share trading around a two year low:

The above share price chart tells any observer that 'something company specific has happened'.  There are just too many 'gaps' on the share chart. 

Before we get onto this, what does the company do? Using the corporate website we get:

'Intuitive Surgical is the global leader in the rapidly emerging field of robotic-assisted minimally invasive surgery. Since its inception, the company has consistently provided surgeons and hospitals with the tools needed to improve clinical outcomes and to help patients return to active and productive lives'.

Laudable aims.  And you can see/understand the basic business model too: sell hospitals/surgeons systems, associated service contracts and relevant instruments and accessories:


The healthcare theme that the company is accessing is that whilst demand is going up...

...patients today want to spend less time away from home, a preference consistent with hospitals/healthcare providers wanting to save money.  I thought that this chart from an Intuitive Surgical report nicely summarises what the company sees as the benefits of its approach:


This sounds great, especially as the company anticipates opportunity in many different procedural areas:
 


 
You can see why, therefore, operating income has shown an impressive progression over recent years. 
 


So what went wrong?  How can we reconcile these impressive thematic observations with the share price chart shown at the start of this posting?

The problems are nicely summarised in this report here.  In summary, what this link says is that:

'No Safety Benefit Found in Use of Robot for Hysterectomy'

“Unfortunately, the greater costs associated with robotic-assisted hysterectomy were not reflected in improvement in outcomes,”

'In July, Sunnyvale, California-based Intuitive said sales growth slowed in the second quarter and that it had received a regulatory warning letter concerning reporting issues for the devices'.

'In the study released yesterday, while patients who got robotic hysterectomies had a lower rate of needing blood transfusions, they had double the risk of getting pneumonia after the operation'.

I think it is possible now to see why the company's shares have struggled materially recently. 

The company is fighting back, telling analysts/investors that the above research failed to take into account that the company's user base tended to be older/have more chronic issues.  Additionally they have been issuing press releases showing research that supports their view that robot surgery is safer (link here) as well as hiking their share buyback to US$1.5bn. 

Recent results have sagged though as shown by this excerpt from the Q2 numbers:


Note in particular how lower systems sales have led to lower income from operations despite the other parts of the business (services, instruments) continuing to perform well.  Why was this?  A mixture of the inevitable global lengthening of decision-making and some of the high profile controversies noted above, in all likelihood.  It is difficult to isolate individual factors but, inevitably, where it leaves H2 sales and 2014 projections will show high variability. 

So, how should we think about valuation?  Well, a market cap of US$14.7bn and an EV of US$13.6bn has to be contrasted with likely income from operations of US$900-930m.  That is still an EV/ebit ratio in the x14s. 

There is still growth hope in the valuation.  It is easy to see why this is given the company's history, but this feels a bit too rich as the growth slowdown is not just exogenous factors (like the economy) related.  At today's price, my instinct is to await the Q3 numbers (16th October) / further updates from the company.  They are facing tough comparatives during H2 and that raises the chances of a further perceived 'miss'.  I will also be looking for insights into safety/perception issues. 

In summary, a fascinating thematic company but too many potential issues today so, for the moment, keep on reviewing. 

2 comments:

  1. ISRG is a big price small float stock like AMZN,
    Chipotle, NetFlix, Priceline, etc. Given that it is profitable it almost certainly will return to its highs, based on its profit, price, and ownership profile. I've never bot such stocks, to my chagrin.

    ReplyDelete
  2. We are manufacturer & exporter

    Products details:
    Surgical Instruments,Dental Instruments,Beauty Instruments,Vetenairy instruments,Eye Instruments,Orthopedics instruments,& Fishing Instruments all kinds.

    Our company ISO 9002, CE MARK, CGMP, FDA U.A.S

    We provide all instruments in best prices and best quality. Our

    instruments made in good steel .I need one chance to prove our self.

    There are lots of items in our stock...

    Our Aim:

    On time delivery

    Best and competitive prices

    Quality in international level

    Best Regards,
    AHAF SURGICO



    Khadim Ali Road Near City Public School

    Sialkot-51330, PAKISTAN
    Mob:+92-3153815958
    E-mail:info@ahafsurgico.com Web:www.ahafsurgico.com

    Skype id:Hassan.mughal48

    Facebook page:https://www.facebook.com/pages/Instruments/504493522927268?ref=hl

    ReplyDelete